Short answer
MERIT MEDICAL SYSTEMS INC (MMSI) filed its fiscal 2025 10-K annual report with the SEC on Feb 24, 2026. It reported revenue of $1.5B (+11.8% year over year) and net income of $128M.
- Top risk flagged: Supply chain reliance on limited sterilization service providers risks production delays if any ceases operation or compliance, potentially halting sales
FY2025 key financial metrics · XBRL
- Revenue
- $1.5B
- +11.8% YoY
- Net income
- $128M
- +6.8% YoY
- Operating margin
- 12.2%
- +0.7 pp YoY
- Gross margin
- 48.7%
- +1.3 pp YoY
- EPS (diluted)
- $2.13
- +4.9% YoY
- ROE
- 8.1%
- −0.6 pp YoY
- Operating cash flow
- $297M
- +34.7% YoY
Source: XBRL data from the MERIT MEDICAL SYSTEMS INC (MMSI) FY2025 10-K on SEC EDGAR. USD.
MERIT MEDICAL SYSTEMS INC FY2025 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business model: design, manufacture, and sell medical devices globally with emphasis on regulatory compliance and product lifecycle management
- Regulatory challenges heightened by EU MDR certification delays, increased costs, and discontinuation of certain products in the E.U. this fiscal year
- Strategic shift toward development of increasingly therapeutic medical products requiring more clinical trials, raising innovation risk and regulatory complexity
- Notable compliance and risk exposure: expanded focus on global anti-bribery laws, extensive healthcare fraud and abuse scrutiny, and evolving privacy/data protection regulations impacting operations
- Environmental and social governance risks addressed with potential impacts from PFAS and ethylene oxide sterilization restrictions and growing corporate social responsibility requirements
Management Discussion & Analysis
- Revenue $1.516B in 2025, up 11.8% YoY ($159.4M increase from $1.357B in 2024), driven by U.S. and EMEA demand
- Gross margin 48.7% in 2025 vs 47.4% in 2024; net income $128.5M (8.5% margin) vs $120.4M (8.9% margin)
- Best segment: Cardiovascular sales $1.443B (+10.9%), operating income $166.1M; Worst: Endoscopy sales $72.9M (+33.0%), operating income $18.6M
- Increased SG&A expenses by $55.5M (13.9%) and R&D by $9.9M (11.3%) in 2025; long-term debt $747.5M, contingent liabilities $4.5M, operating leases $87.5M
- Management highlights multi-year Continued Growth initiatives through 2026; key risks include increased effective tax rate (24.8% vs 19.8%) and foreign currency fluctuations
Risk Factors
- Supply chain reliance on limited sterilization service providers risks production delays if any ceases operation or compliance, potentially halting sales
- Geopolitical tensions in Ukraine, Middle East, Venezuela increasing supply interruptions, elevating cost pressures on petroleum-based materials critical to manufacturing
- China’s Value-Based Purchasing (VBP) policy since 2022 negatively impacting pricing and revenue, with continued adverse effects expected in 2026
- Competition from larger medical device firms and tech entrants with greater AI integration capabilities threatening market share and product relevance
- CEO transition in Oct 2025 to Martha G. Aronson, with no key man insurance; potential disruption or loss of institutional knowledge poses material business risk
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.